Literature DB >> 12020773

Gossypol: a contraceptive for men.

Elsimar Metzker Coutinho1.   

Abstract

Gossypol is a polyphenol isolated from the seed, roots, and stem of the cotton plant (Gossypium sp.). The substance, a yellow pigment similar to flavonoids, is present in cottonseed oil. In the plant, it acts as a natural defensive agent against predators, provoking infertility in insects. In most animals, gossypol provokes infertility, and in man it causes spermatogenesis arrest at relatively low doses. Studies carried out in China, Africa, and Brazil have shown that the substance is well tolerated, causing no side effects that lead to discontinuation. The reported hypokalemia of early studies has not been confirmed in the latest trials. The only concern at present appears to be lack of reversibility in over 20% of subjects. Gossypol should be prescribed preferably to men who have completed their families or for those who would accept permanent infertility after a few years of use.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12020773     DOI: 10.1016/s0010-7824(02)00294-9

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  38 in total

Review 1.  Effects of plants and plant products on the testis.

Authors:  Shereen Cynthia D'Cruz; Selvaraju Vaithinathan; Rajamanickam Jubendradass; Premendu Prakash Mathur
Journal:  Asian J Androl       Date:  2010-06-21       Impact factor: 3.285

Review 2.  Delivering non-hormonal contraceptives to men: advances and obstacles.

Authors:  Dolores D Mruk; C Yan Cheng
Journal:  Trends Biotechnol       Date:  2008-01-11       Impact factor: 19.536

3.  Gene expression profiling during gland morphogenesis of a mutant and a glandless upland cotton.

Authors:  Quan Sun; Yingfan Cai; Yongfang Xie; Jianchuan Mo; Youlu Yuan; Yuzhen Shi; Shengwei Li; Huaizhong Jiang; Zheng Pan; Yunling Gao; Min Chen; Xiaohong He
Journal:  Mol Biol Rep       Date:  2009-11-04       Impact factor: 2.316

4.  Anti-inflammatory Effects of Gossypol on Human Lymphocytic Jurkat Cells via Regulation of MAPK Signaling and Cell Cycle.

Authors:  Chien-Wei Chen; Sindy Hu; Ke-Hung Tsui; Guey-Shyang Hwang; Szu-Tah Chen; Tswen-Kei Tang; Hao-Tsai Cheng; Ju-Wen Yu; Hsiao-Chiu Wang; Horng-Heng Juang; Paulus S Wang; Shyi-Wu Wang
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

Review 5.  Structural and Chemical Biology of Terpenoid Cyclases.

Authors:  David W Christianson
Journal:  Chem Rev       Date:  2017-08-25       Impact factor: 60.622

6.  Enhanced Neuronal Survival and Neurite Outgrowth Triggered by Novel Small Organic Compounds Mimicking the LewisX Glycan.

Authors:  Thomas Theis; Anmol Singh Johal; Maciej Kabat; Sayantani Basak; Melitta Schachner
Journal:  Mol Neurobiol       Date:  2018-03-08       Impact factor: 5.590

7.  A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer.

Authors:  Maria Q Baggstrom; Yingwei Qi; Marianna Koczywas; Athanassios Argiris; Elizabeth A Johnson; Michael J Millward; Sara C Murphy; Charles Erlichman; Charles M Rudin; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2011-10       Impact factor: 15.609

Review 8.  Bcl-2 antagonists: a proof of concept for CLL therapy.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Invest New Drugs       Date:  2013-08-02       Impact factor: 3.850

9.  Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway.

Authors:  Luyuan Zhang; Sinan Sun; Yumin Wang; Yongzhen Mo; Fang Xiong; Shanshan Zhang; Zhaoyang Zeng; Wei Xiong; Guiyuan Li; Hao Chen; Can Guo
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

10.  A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.

Authors:  William R Schelman; Tabraiz A Mohammed; Anne M Traynor; Jill M Kolesar; Rebecca M Marnocha; Jens Eickhoff; Michael Keppen; Dona B Alberti; George Wilding; Naoko Takebe; Glenn Liu
Journal:  Invest New Drugs       Date:  2013-07-17       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.